William Blair & Company’s Akebia Therapeutics AKBA Stock Holding History

William Blair & Company’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,599	Closed	-$38K	–	1909
2021 Q4	$38K	Sell	16,599 -6,306	-28%	-$17.2K	﹤0.01%	1798
2021 Q3	$66K	Sell	22,905 -4,058	-15%	-$11.6K	﹤0.01%	1655
2021 Q2	$102K	Hold	26,963	–	–	﹤0.01%	1610
2021 Q1	$91K	Buy	26,963 +1,411	+6%	+$5.08K	﹤0.01%	1605
2020 Q4	$72K	Sell	25,552 -47,250	-65%	-$138K	﹤0.01%	1581
2020 Q3	$183K	Buy	72,802 +9,252	+15%	+$81.2K	﹤0.01%	1332
2020 Q2	$863K	Sell	63,550 -1,243	-2%	-$12.9K	﹤0.01%	758
2020 Q1	$491K	Hold	64,793	–	–	﹤0.01%	873
2019 Q4	$409K	Sell	64,793 -8,608	-12%	-$40.9K	﹤0.01%	1063
2019 Q3	$288K	Sell	73,401 -2,000	-3%	-$8.57K	﹤0.01%	1133
2019 Q2	$365K	Hold	75,401	–	–	﹤0.01%	1087
2019 Q1	$618K	Buy	75,401 +5,826	+8%	+$40K	﹤0.01%	895
2018 Q4	$385K	Buy	+69,575	New	+$544K	﹤0.01%	993

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OCM

Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

William Blair & Company's AKBA Position: Q1 2022 in Review

William Blair & Company sold out of Akebia Therapeutics (AKBA) in Q1 2022, closing a stake of 16,599 shares — an estimated $38K sold.

William Blair & Company first reported a position in AKBA in Q4 2018 and held it in 13 quarters. The position peaked at $863K in Q2 2020. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

William Blair & Company reported no remaining Akebia Therapeutics position as of Q1 2022 after selling out during the quarter.
William Blair & Company sold 16,599 Akebia Therapeutics shares in Q1 2022, an estimated $38K.
William Blair & Company first reported a position in Akebia Therapeutics in Q4 2018 and held it in 13 quarters.
William Blair & Company's Akebia Therapeutics position peaked at $863K in Q2 2020.
124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.